Literature DB >> 8094762

Alpha 1 adrenoceptor subtypes in the human prostate.

H Lepor1, R Tang, S Meretyk, E Shapiro.   

Abstract

High affinity alpha 1 adrenoceptors have been characterized in the human prostate. The tension of prostatic smooth muscle is mediated by the alpha 1 adrenoceptor. The present study represents the first characterization of human alpha 1 adrenoceptor subtypes using radioligand receptor binding techniques. Binding studies were performed on tissue homogenates obtained from the human prostate. Competitive inhibition studies were performed in the presence of an 80 pM. 125I-Heat and 16 concentrations of unlabelled 5-methylurapidil (5 MU) or WB-4101 (10(-10) M. to 10(-5) M.). Saturation experiments were also performed with and without chloroethylclonidine (CEC, 10(-5) M.), a compound that selectively inactivates the alpha 1B subtype. The individual displacement plots for WB-4101 and 5-MU in the human prostate were consistently best fit by a 2 binding site model. WB-4101 and 5-MU exhibited a 594- and 186-fold higher affinity for the prostatic alpha 1A binding site relative to the alpha 1B binding site. The ratios of prostatic alpha 1A/alpha 1B binding sites discriminated by WB-4101 and 5-MU were 1.8 and 1.6, respectively. CEC inactivated 44% of the prostatic alpha 1 binding sites. The binding studies suggest that the dominant alpha 1 subtype in the human prostate is the alpha 1A. We are characterizing the functional properties of the alpha 1 subtypes in the human prostate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094762     DOI: 10.1016/s0022-5347(17)36170-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  Factors influencing biased agonism in recombinant cells expressing the human α1A -adrenoceptor.

Authors:  Edilson Dantas da Silva Junior; Masaaki Sato; Jon Merlin; Natalie Broxton; Dana S Hutchinson; Sabatino Ventura; Bronwyn A Evans; Roger J Summers
Journal:  Br J Pharmacol       Date:  2017-06-10       Impact factor: 8.739

2.  The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2006

Review 3.  Is Tamsulosin Linked to Dementia in the Elderly?

Authors:  Jason K Frankel; Yinghui Duan; Peter C Albertsen
Journal:  Curr Urol Rep       Date:  2018-07-03       Impact factor: 3.092

4.  Characterization of alpha 1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation.

Authors:  J H Guh; S C Chueh; F N Ko; C M Teng
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

5.  Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy.

Authors:  K Shibata; A Hirasawa; N Moriyama; K Kawabe; S Ogawa; G Tsujimoto
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

6.  Alpha blockers for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2007

7.  Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery.

Authors:  A Hatano; H Takahashi; M Tamaki; T Komeyama; T Koizumi; M Takeda
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

8.  A1 and A2A adenosine receptor modulation of alpha 1-adrenoceptor-mediated contractility in human cultured prostatic stromal cells.

Authors:  A Preston; M Frydenberg; J M Haynes
Journal:  Br J Pharmacol       Date:  2004-01       Impact factor: 8.739

Review 9.  Alpha-blockers: an effective treatment for prostatitis?

Authors:  D Caropreso; T D Moon
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

Review 10.  Benign prostatic hyperplasia. Current pharmacological treatment.

Authors:  M Jønler; M Riehmann; R C Bruskewitz
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.